Question-and-Answer Session
Operator
Thank you. (Operator Instructions)
And your first question comes from the line of Ted Tenthoff with Piper Jaffray.
Ted Tenthoff - Piper Jaffray
Great. Thank you very much. Can you hear me at here Michael?
Michael Kauffman
We can.
Ted Tenthoff - Piper Jaffray
Great. How are you?
Michael Kauffman
Good.
Ted Tenthoff - Piper Jaffray
Two quick questions, one just a little housekeeping. Kim, I didn't hear what was the net loss guidance for the year? And then, Michael, if you can, you went into a little bit of detail about the Phase 2b that you'll be starting this year in Alzheimer's disease in the first half, can give us a little bit more color on what you might be doing in terms of size of that trial, will that be an international trial? What's your current thinking on the kind of next steps there?
Kim Drapkin
Okay. Ted, thank you for your questions. The net loss guidance for 2008 is $45 million to $50 million.
Ted Tenthoff - Piper Jaffray
Okay. Great. Thank you.
Kim Drapkin
Michael?
Michael Kauffman
Sure. Ted, on the question of the Alzheimer's program, which we're working with Glaxo to design. This is a program given the data that we received, obtained in the Phase 2a, there is interest on both sides in looking at both monotherapy and in combination therapy moving ahead. So, we haven't finalized the program yet, but our expecting is, is that there are likely to be two trials. The length of the trials will be on the order of 12 weeks, possibly longer, possibly 12 weeks for the monotherapy and possibly longer for the combination study.
The combination study will be carried out with our drug in combination with Aricept, as compared to Aricept alone. And the monotherapy study is for patients who are naïve to cognitive therapy. The plan is that as we stand now that the trials will be conducted in United States.
Ted Tenthoff - Piper Jaffray
Great. That's very helpful. Good luck with that.
Michael Kauffman
Thank you.
Kim Drapkin
Thanks, Ted.
Operator
And your next question comes from the line of Alan Carr with Needham.
Alan Carr - Needham & Company
Hi, good morning, everyone.
Kim Drapkin
Good morning, Alan.
Alan Carr - Needham & Company
I was wondering if you could give us a little more information about the plans for 7034 and I recall that you were going to explore one of the enantiomers in obesity. So could you go through over your thought process behind the plans for 2008 with this drug?
- To read the full transcript on Seeking Alpha, click here »
